Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975161 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2TDP1HPGDPOLB | |
| SCHEMBL22403857 | 0.84 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL12454178 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL24926282 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL24926262 | 0.83 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL18799808 | 0.83 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL10101745 | 0.81 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL11985629 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL26021892 | 0.79 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL24926253 | 0.78 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TDP1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | ALDH1A1 3787/4885SMN1; SMN2 2381/4885TDP1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.